LOS ANGELES, CA / ACCESS Newswire / February 5, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

RBC Capital lowered the firm’s price target on Regeneron (REGN) to $1,045 from $1,059 but keeps an Outperform rating on the shares. The ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the second trading day of the week. The company posted its fourth-quarter and ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is an American biotechnology company that is focused on developing and commercializing medicines for patients with a range of diseases, including eye ...

Regeneron and Illumina have joined a major ... of genotypic and phenotypic information ever assembled," claims the company. It will tap into Truveta's platform – based on electronic medical ...

Regeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and commercialise drugs targeting eye, central nervous system (CNS ...

Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our ...